Codiak BioSciences. has filed a patent for compositions and methods involving extracellular vesicles containing nucleic acid targeting genes to polarize tumor-associated macrophages. The claim focuses on extracellular vesicles with immunomodulating components that repolarize macrophages from M2 to M1 phenotype for cancer treatment. GlobalData’s report on Codiak BioSciences gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData


Data Insights Codiak BioSciences Inc - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on Codiak BioSciences, Peptide pharmacophores was a key innovation area identified from patents. Codiak BioSciences's grant share as of January 2024 was 9%. Grant share is based on the ratio of number of grants to total number of patents.

Extracellular vesicles for repolarizing macrophages in cancer treatment

Source: United States Patent and Trademark Office (USPTO). Credit: Codiak BioSciences Inc

A recently filed patent (Publication Number: US20230365971A1) describes an extracellular vesicle containing immunomodulating components that can repolarize macrophages from an M2 to an M1 phenotype upon contact. These components include antisense oligonucleotides (ASO) or inhibitory RNAs targeting specific genes like KRAS, HIF1-alpha, and STAT3. The extracellular vesicle, which can be an exosome, aims to target tumor-associated macrophages in conditions like pancreatic cancer. Additionally, the patent mentions the inclusion of additional immunomodulating components like small molecule drugs, antibodies, or therapeutic proteins to enhance the therapeutic effect.

Furthermore, the patent outlines methods for treating diseases, particularly cancer, by administering the extracellular vesicle to modulate gene expression in macrophages. By increasing the secretion of inflammatory cytokines and decreasing immunosuppressive factors, the repolarized macrophages are expected to enhance the stimulation of CD8+ T-cells and Natural Killer cells. The patent also includes a specific method for treating pancreatic cancer by targeting human wild-type KRAS with inhibitory RNA, leading to a more significant polarization of tumor-resident macrophages compared to targeting KRASG12D. These innovative approaches highlight the potential of extracellular vesicles in immunotherapy and cancer treatment.

To know more about GlobalData’s detailed insights on Codiak BioSciences, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies